Nanomedicine News RSS Feed - Nanomedicine

First Patient Dosed in Cerulean CRLX301 Nanoparticle-Drug Conjugate Trial for Advanced Solid Tumors

First Patient Dosed in Cerulean CRLX301 Nanoparticle-Drug Conjugate Trial for Advanced Solid Tumors

Cerulean Pharma Inc., a leader in Dynamic Tumor Targeting™, today announced that the first patient has been dosed with CRLX301 in Cerulean’s Phase 1/2a trial in patients with advanced solid tumor malignancies. CRLX301 is a nanoparticle-drug conjugate, or NDC, with a docetaxel payload, and it is the second clinical candidate from Cerulean’s Dynamic Tumor Targeting Platform. [More]
Distinguished Contributor to Green Nanotechnology and Nanomedicine Elected into Fellowship of National Academy of Inventors

Distinguished Contributor to Green Nanotechnology and Nanomedicine Elected into Fellowship of National Academy of Inventors

Nanomedicine is the medical application of nanotechnology, or the use of microscopic structures to diagnose, image, treat and prevent disease. Current problems in nanomedicine include understanding and anticipating the potentially toxic impact these nanostructures have on the body and the environment once they're released. [More]
Nanoparticle System Decorated with Nanobodies to Locate Cellular Source of Brain Damage

Nanoparticle System Decorated with Nanobodies to Locate Cellular Source of Brain Damage

Traumatic brain injury is currently revealed by using a series of physiological and cognitive tests along with standard medical imaging, such as magnetic resonance imaging (MRI). The techniques are excellent for diagnosis of moderate to severe traumatic brain injury, but less effective for diagnosing mild injury and for predicting the extent of its impact. [More]
NetScientific Invests in PDS Biotechnology

NetScientific Invests in PDS Biotechnology

NetScientific, the biomedical and healthcare technology group, today announced it has made an investment in PDS Biotechnology Corporation (‘PDS’). [More]
Cristal Therapeutics Completes New €6 Million Financing Round

Cristal Therapeutics Completes New €6 Million Financing Round

Biopharmaceutical company Cristal Therapeutics has completed a new financing round of over €6 million which includes investments from new and existing investors and a national innovation fund. Venture capital investor Chemelot Ventures joins as a new shareholder and existing investors Thuja Capital, BioGeneration Ventures, Nedermaas, Utrecht University Holding and Beheer Innovatiefonds Provincie Limburg also contributed. [More]
Gold Nanoparticle Sensor System Can Accurately Profile Anti-Cancer Drugs

Gold Nanoparticle Sensor System Can Accurately Profile Anti-Cancer Drugs

Traditional genomic, proteomic and other screening methods currently used to characterize drug mechanisms are time-consuming and require special equipment, but now researchers led by chemist Vincent Rotello at the University of Massachusetts Amherst offer a multi-channel sensor method using gold nanoparticles that can accurately profile various anti-cancer drugs and their mechanisms in minutes. [More]
NantWorks and Sorrento to Establish The Immunotherapy Antibody JV

NantWorks and Sorrento to Establish The Immunotherapy Antibody JV

Sorrento Therapeutics, Inc., an oncology company developing new treatments for cancer and associated pain, announced today that it has entered into a binding agreement with NantWorks founder, physician scientist, and biotechnology entrepreneur Dr. Patrick Soon-Shiong. [More]
Nanomaterial Coatings Improve Strength, Biocompatibility of Hip and Knee Replacements

Nanomaterial Coatings Improve Strength, Biocompatibility of Hip and Knee Replacements

Washington State University researchers are working to improve materials used in hip and knee replacements so that they last longer and allow patients to quickly get back on their feet after surgery. [More]
COBRA PzF Stent System with Polyzene-F Nano-Thin Coating Safe for Heart Disease Treatment

COBRA PzF Stent System with Polyzene-F Nano-Thin Coating Safe for Heart Disease Treatment

CeloNova BioSciences, Inc., today announced results from a First-in-Man (FIM) clinical trial presented by Luc Maillard, MD PhD, at the prestigious French Cardiology Meeting, GRCI, held in Paris, France. In his presentation entitled, “First-in-man expérience avec le stent Cobra-PzF, utilisant un nano-coating,” Dr. Maillard concluded that the COBRA PzF™ coronary stent system with advanced nano-thin coating of Polyzene™-F polymer can be a safe and effective interventional treatment for real-world and complex patients with heart disease. [More]
Fast Pulsed Magnetic Fields Help Focus Nano-Therapeutic Magnetic Particles to Deep Targets

Fast Pulsed Magnetic Fields Help Focus Nano-Therapeutic Magnetic Particles to Deep Targets

Recent efforts between the University of Maryland (UMD) and Bethesda-based Weinberg Medical Physics LLC (WMP) have led to a new technique to magnetically deliver drug-carrying particles to hard-to-reach targets. The method has the potential to transform the way deep-tissue tumors and other diseases are treated. [More]